Capricor Therapeutics
CAPR
29 hedge funds and large institutions have $8.87M invested in Capricor Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.21% less ownership
Funds ownership: 10.67% → 10.46% (-0.21%)
1% less capital invested
Capital invested by funds: $8.95M → $8.87M (-$72.7K)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
23% less call options, than puts
Call options by funds: $932K | Put options by funds: $1.21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$404K |
| 2 |
B
Bailard
Foster City,
California
|
+$106K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$79.7K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$74.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWM
Selective Wealth Management
Forest,
Virginia
|
-$732K |
| 2 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$64K |
| 3 |
Goldman Sachs
New York
|
-$61.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$55.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$41.7K |
CAPR Hedge Fund Activity: Q2 2022 in Review
29 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2022, worth a combined $8.87M — down 0.81% from $8.95M a quarter earlier.
Fund positioning in CAPR was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $404K. The largest seller was Selective Wealth Management, exiting entirely with an estimated $732K sold.
- 29 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $8.87M of Capricor Therapeutics stock for Q2 2022, down 0.81% quarter-over-quarter.
- 4 funds opened new Capricor Therapeutics positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest Capricor Therapeutics buyer in Q2 2022 was Vanguard Group, an estimated $404K added.
- The largest Capricor Therapeutics seller in Q2 2022 was Selective Wealth Management, an estimated $732K sold.
Based on aggregated 13F filings for Q2 2022.